Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Novo Nordisk A/S
Study ID
NCT02963922
Phase
PHASE3
Status
Completed

Conditions

  • Metabolism and Nutrition Disorder
  • Obesity

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide 3.0 mg — DRUG
    Injected subcutaneously (s.c., under the skin) once daily
  • Placebo — DRUG
    Injected subcutaneously (s.c., under the skin) once daily

Study Details

This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.

Key Dates

Start date
Feb 6, 2017
Status verified
Mar 2020
Primary completion
Sep 10, 2018
Completion
Sep 25, 2018

Study Design

Enrollment
396 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: liraglutide 3.0 mg
  • Placebo Comparator: Placebo

Primary Outcome Measure

Change in Body Weight (%) [ Time Frame: Week 0, week 56 ]

Locations (19)

FacilityCityStateZIPSite coordinators
Novo Nordisk Investigational SiteBirminghamAlabama35294-
Novo Nordisk Investigational SiteConcordCalifornia94520-
Novo Nordisk Investigational SiteFresnoCalifornia93720-
Novo Nordisk Investigational SiteJacksonvilleFlorida32205-
Novo Nordisk Investigational SitePlantationFlorida33324-
Novo Nordisk Investigational SiteRoswellGeorgia30076-
Novo Nordisk Investigational SiteHonoluluHawaii96814-
Novo Nordisk Investigational SiteChicagoIllinois60607-
Novo Nordisk Investigational SiteLouisvilleKentucky40213-
Novo Nordisk Investigational SiteNorth DartmouthMassachusetts02747-
Novo Nordisk Investigational SiteMinneapolisMinnesota55416-
Novo Nordisk Investigational SiteButteMontana59701-
Novo Nordisk Investigational SiteAlbanyNew York12206-
Novo Nordisk Investigational SiteWilmingtonNorth Carolina28401-
Novo Nordisk Investigational SiteAustinTexas78731-
Novo Nordisk Investigational SiteAustinTexas78749-
Novo Nordisk Investigational SiteDallasTexas75230-
Novo Nordisk Investigational SiteDallasTexas75231-
Novo Nordisk Investigational SiteWinchesterVirginia22601-3834-

Find similar trials in Birmingham, AL

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Novo Nordisk Investigational Site· Birmingham, ALNovo Nordisk Investigational Site· Concord, CANovo Nordisk Investigational Site· Fresno, CANovo Nordisk Investigational Site· Jacksonville, FLNovo Nordisk Investigational Site· Plantation, FLNovo Nordisk Investigational Site· Roswell, GA

Related Studies